Header Logo

Connection

BRYAN BURT to Lung Neoplasms

Back to Details
This is a "connection" page, showing publications BRYAN BURT has written about Lung Neoplasms.
BRYAN BURT
Connection Strength
9.188
Lung Neoplasms
  1. A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2023 02 01; 29(3):548-559.
    View in: PubMed
    Score: 0.420
  2. Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment. Cancer Res. 2022 07 18; 82(14):2593-2609.
    View in: PubMed
    Score: 0.405
  3. Commentary: The structure of structural racism revealed by lung cancer screening. J Thorac Cardiovasc Surg. 2022 06; 163(6):1931-1932.
    View in: PubMed
    Score: 0.381
  4. Commentary: The A, C, G, and Ts of differentiating stage I and stage IV lung cancer. J Thorac Cardiovasc Surg. 2020 08; 160(2):e83-e84.
    View in: PubMed
    Score: 0.341
  5. Preoperative prediction of unresectability in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2020 06; 159(6):2512-2520.e1.
    View in: PubMed
    Score: 0.337
  6. Commentary: Usurping the king: A step toward planning a biological checkmate on non-small cell lung carcinoma. J Thorac Cardiovasc Surg. 2019 09; 158(3):922-923.
    View in: PubMed
    Score: 0.326
  7. Commentary: Postoperative blood transplantation for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019 06; 157(6):2480-2481.
    View in: PubMed
    Score: 0.318
  8. To slay a dragon: Timing of chemotherapy in resectable pleural mesothelioma. J Thorac Cardiovasc Surg. 2019 02; 157(2):767-768.
    View in: PubMed
    Score: 0.313
  9. A thinner peel to peel: Pleural thickness is prognostic in mesothelioma. J Thorac Cardiovasc Surg. 2019 01; 157(1):414-415.
    View in: PubMed
    Score: 0.312
  10. Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI Insight. 2018 04 05; 3(7).
    View in: PubMed
    Score: 0.301
  11. Therapeutic R2 resection for pleural mesothelioma. J Thorac Cardiovasc Surg. 2018 06; 155(6):2734-2735.
    View in: PubMed
    Score: 0.297
  12. The importance of R0. J Thorac Cardiovasc Surg. 2018 01; 155(1):428-429.
    View in: PubMed
    Score: 0.296
  13. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma. Ann Thorac Surg. 2017 Nov; 104(5):1679-1687.
    View in: PubMed
    Score: 0.290
  14. Programmed death ligand 1-associated antitumor immunity in early-stage non-small cell lung cancer: Expression of major histocompatibility complex I as a prerequisite. J Thorac Cardiovasc Surg. 2018 01; 155(1):393-394.
    View in: PubMed
    Score: 0.289
  15. Incompletely resected non-small cell lung cancer: Do we know how to handle a positive margin? J Thorac Cardiovasc Surg. 2017 08; 154(2):673-674.
    View in: PubMed
    Score: 0.281
  16. Overall Survival Following Thoracoscopic vs Open Lobectomy for Early-stage Non-small Cell Lung Cancer: A Meta-analysis. Semin Thorac Cardiovasc Surg. 2017 Spring; 29(1):104-112.
    View in: PubMed
    Score: 0.279
  17. Clarity and clairvoyance: Review and prediction of management guidelines for early stage lung cancer. J Thorac Cardiovasc Surg. 2017 06; 153(6):1563-1564.
    View in: PubMed
    Score: 0.278
  18. Thoracoscopic lobectomy for clinical N2 and N1 lung cancer: Innovation outpacing standard of care. J Thorac Cardiovasc Surg. 2017 04; 153(4):977-978.
    View in: PubMed
    Score: 0.276
  19. Radiography nomography: Utility of a calculator in rational preoperative decision making for subsolid pulmonary nodules. J Thorac Cardiovasc Surg. 2017 02; 153(2):460-461.
    View in: PubMed
    Score: 0.273
  20. Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages. Clin Cancer Res. 2017 Feb 01; 23(3):778-788.
    View in: PubMed
    Score: 0.268
  21. Invited Commentary. Ann Thorac Surg. 2015 Nov; 100(5):1874.
    View in: PubMed
    Score: 0.254
  22. Diameter of Solid Tumor Component Alone Should be Used to Establish T Stage in Lung Adenocarcinoma. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1318-23.
    View in: PubMed
    Score: 0.250
  23. CTLA4 blockade in patients with malignant mesothelioma. Lancet Respir Med. 2015 Apr; 3(4):261-3.
    View in: PubMed
    Score: 0.244
  24. A meta-analysis of resected metachronous second non-small cell lung cancer. Ann Thorac Surg. 2015 Apr; 99(4):1470-8.
    View in: PubMed
    Score: 0.243
  25. Improved detection of stage I non-small cell lung cancer with a serum-based assay. J Thorac Cardiovasc Surg. 2015 Mar; 149(3):735-6.
    View in: PubMed
    Score: 0.239
  26. Thoracoscopic lobectomy is associated with acceptable morbidity and mortality in patients with predicted postoperative forced expiratory volume in 1 second or diffusing capacity for carbon monoxide less than 40% of normal. J Thorac Cardiovasc Surg. 2014 Jul; 148(1):19-28, dicussion 28-29.e1.
    View in: PubMed
    Score: 0.227
  27. Repeated and aggressive pulmonary resections for leiomyosarcoma metastases extends survival. Ann Thorac Surg. 2011 Oct; 92(4):1202-7.
    View in: PubMed
    Score: 0.190
  28. Pleurectomy and decortication are associated with better survival for bicavitary cytoreductive surgery for mesothelioma compared with extrapleural pneumonectomy. J Thorac Cardiovasc Surg. 2023 05; 165(5):1722-1730.
    View in: PubMed
    Score: 0.104
  29. Chronic exposure to carbon black ultrafine particles reprograms macrophage metabolism and accelerates lung cancer. Sci Adv. 2022 11 18; 8(46):eabq0615.
    View in: PubMed
    Score: 0.104
  30. A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma. Br J Cancer. 2022 11; 127(9):1691-1700.
    View in: PubMed
    Score: 0.102
  31. A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma. Genome Med. 2022 01 12; 14(1):5.
    View in: PubMed
    Score: 0.098
  32. Reply to Waller et?al. Standardizing Surgical Treatment for Mesothelioma. J Thorac Oncol. 2020 05; 15(5):e75-e77.
    View in: PubMed
    Score: 0.087
  33. Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors. J Thorac Cardiovasc Surg. 2020 04; 159(4):1598-1610.e3.
    View in: PubMed
    Score: 0.084
  34. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 10; 14(10):1718-1731.
    View in: PubMed
    Score: 0.083
  35. A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce. J Thorac Oncol. 2019 08; 14(8):1343-1353.
    View in: PubMed
    Score: 0.081
  36. Commentary: Adjuvant intensity-modulated radiation therapy for malignant pleural mesothelioma: Suspension of intention. J Thorac Cardiovasc Surg. 2019 09; 158(3):932-933.
    View in: PubMed
    Score: 0.080
  37. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2018 11; 13(11):1655-1667.
    View in: PubMed
    Score: 0.078
  38. IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer. Cancer Immunol Res. 2018 06; 6(6):645-657.
    View in: PubMed
    Score: 0.075
  39. Matrix metalloproteinase 12 promotes tumor propagation in the lung. J Thorac Cardiovasc Surg. 2018 05; 155(5):2164-2175.e1.
    View in: PubMed
    Score: 0.075
  40. Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity. JCI Insight. 2016 11 03; 1(18):e89020.
    View in: PubMed
    Score: 0.068
  41. Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy. Semin Oncol. 2014 Feb; 41(1):40-56.
    View in: PubMed
    Score: 0.056
  42. A dominant adenocarcinoma with multifocal ground glass lesions does not behave as advanced disease. Ann Thorac Surg. 2013 Aug; 96(2):411-8.
    View in: PubMed
    Score: 0.054
  43. Diameter of non-small cell lung cancer correlates with long-term survival: implications for T stage. Chest. 2005 Nov; 128(5):3255-60.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.